Evidence map›Paper›PMID 31813921›Full record

ArticleAnnals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia2020

Neutrophil Elastase Inhibitor Sivelestat Attenuates Myocardial Injury after Cardioplegic Arrest in Rat Hearts.

Masahiro Fujii, Ryuzo Bessho

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07118930 (Prospective Double-Blind Controlled Study of Sivelestat Sodium in the Perioperative Management of Off-Pump Coronary Artery Bypass Grafting), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07118930 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Prospective Double-Blind Controlled Study of Sivelestat Sodium in the Perioperative Management of Off-Pump Coronary Artery Bypass Grafting

TypeinterventionalSponsorAffiliated Hospital of Nantong UniversityRan2025 to 2027Enrolled62ConditionsCoronary Heart Disease, Coronary Artery Disease, Coronary Arterial Disease (CAD)ArmsSivelestat Sodium injection 2 h after OPCABG for 72 h, Saline (0.9% NaCl)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Role of Neutrophils on the Ocular Surface.International journal of molecular sciences · 2021
    Pooled it
  2. Trial
  3. Determining optimal pretreatment in cardiac surgery: an experimental study.General thoracic and cardiovascular surgery · 2025
    Article
  4. Article
  5. Do we correctly calculate doses of cardioplegia during aortic valve replacement procedures? A preliminary report.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2023
    Article
  6. Neutrophil degranulation and myocardial infarction.Cell communication and signaling : CCS · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Masahiro FujiiCardiovascular Surgery, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Chiba, Japan.
Ryuzo BesshoCardiovascular Surgery, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Chiba, Japan.
Chiba Hokusou Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSivelestat, a neutrophil elastase inhibitor, attenuates global ischemia-induced myocardial damage and coronary endothelial dysfunction. Here, we investigated whether sivelestat exerts the cardioprotective effects against cardioplegic arrest in rat hearts.

methodsIsolated Langendorff-perfused rat hearts were randomly allocated to three groups and subjected to 2-min infusions with St. Thomas' Hospital cardioplegic solution No. 2 (STH2) and 30-min global ischemia followed by 60-min reperfusion as follows: (i) control (STH2 treatment only), (ii) sivelestat (19 μmol/L) infusion for the first 10 min of reperfusion, and (iii) sivelestat (19 μmol/L) infusion for 10 min before ischemia and for the first 10 min of reperfusion. Left ventricular developed pressure (LVDP) recovery and troponin T leakage were measured at the end of reperfusion. Coronary flow response to acetylcholine (ACh) was assessed.

resultsSingle and multiple doses of sivelestat significantly improved LVDP recovery (69 ± 15 and 69 ± 14 vs 48 ± 15 [control]; p <0.05) and decreased troponin T leakage (0.4 ± 0.3 and 0.7 ± 0.5 vs 1.7 ± 0.6 [control]; p <0.05). Multiple doses of sivelestat significantly improved coronary flow response to ACh (121 ± 9 vs 105 ± 4; p <0.05).

conclusionsAddition of sivelestat to STH2 attenuates myocardial injury after cardioplegic arrest in rat hearts. This cardioprotective effect was achieved even when sivelestat was administered during early reperfusion.

Indexed as

AnimalsDisease Models, AnimalGlycineHeart Arrest, InducedIsolated Heart PreparationLeukocyte ElastaseMaleMyocardial Reperfusion InjuryMyocytes, CardiacRats, WistarSerine Proteinase InhibitorsSulfonamidesTroponin TVentricular Function, LeftVentricular PressureElane protein, ratGlycineLeukocyte ElastaseSerine Proteinase InhibitorssivelestatSulfonamidesTroponin Tcardioplegiaischemia–reperfusionmyocardial protectionratsivelestat

Identifiers

PMID31813921
PMCPMC7641891
OpenAlexW2993636201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.